Warren R P, Storb R, Thomas E D
Transplantation. 1982 Nov;34(5):280-3. doi: 10.1097/00007890-198211000-00008.
Marrow graft rejection after transplantation from an HLA-identical sibling for the treatment of aplastic anemia has an immunological basis in most cases. We previously studied the post-transplantation sera of 20 consecutive patients using the chromium release assays of complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell-mediated cytotoxicity (ADCC). Reactivity against peripheral blood mononuclear cells of the marrow donors was found which was associated with graft rejection. Sera of 17 consecutive patients who rejected their grafts have now been studied. Donor cells susceptible to cytotoxicity in both the CDC and ADCC assays were composed of both adherent and nonadherent cells not forming spontaneous rosettes with sheep red blood cells. Absorption studies demonstrated that the reactivities were mediated by antibody, and inhibition studies with 2-mercaptoethanol indicated that the active component was IgM.
在大多数情况下,从 HLA 同型同胞供体移植治疗再生障碍性贫血后发生的骨髓移植排斥反应具有免疫学基础。我们之前使用补体依赖性细胞毒性(CDC)和/或抗体依赖性细胞介导的细胞毒性(ADCC)的铬释放试验,对 20 例连续患者的移植后血清进行了研究。发现针对骨髓供体外周血单个核细胞的反应性与移植排斥相关。现在对 17 例连续发生移植排斥的患者的血清进行了研究。在 CDC 和 ADCC 试验中易受细胞毒性作用的供体细胞由不与绵羊红细胞形成自发玫瑰花结的贴壁细胞和非贴壁细胞组成。吸收研究表明,这些反应性是由抗体介导的,用 2-巯基乙醇进行的抑制研究表明活性成分是 IgM。